- OVERVIEW AND WHY SHOULD YOU ATTEND
- AREAS COVERED AND LEARNING OBJECTIVES
- WHO WILL BENEFIT
Up until a few years ago FDA required pharmaceutical companies to duplicate the same studies that were required in adults in children. This requirement often prevented development in children because of time, money, and difficulty in running these studies in children.
In 2002 and 2003 Congress enacted laws that allowed pharmaceutical companies to utilize existing adult data to support a pediatric program. During the following two years 70 drugs for adults received approval for a pediatric indication. In 2012 Congress followed up with a law that applied what had been learned following 2003.
This webinar will review the two laws passed in 2002 and 2003: Best Pharmaceuticals for Children Act (BPCA) and Pediatric Research Equity Act (PREA) and review what pharmaceutical companies did in response to these laws. The FDA Safety and Innovation Act of 2012 (FDASIA) will also be described and how it changed the development process.
Understanding the FDA approach to pharmaceutical and clinical development in pediatric patients will allow those responsible for planning and implementation of the company to plan effectively. This webinar will benefit formulation development, preclinical, clinical, and regulatory scientists in pharmaceutical companies and clinical research organizations (CRO) that are developing an indication for pediatric patients. Also, pediatricians who want to be investigators in pediatric clinical studies sponsored by pharmaceutical companies will give them a better idea of what a company wants done before the meet with the company.
why should you attend
This webinar will benefit Ph.D., M.D., Master’s, and B.S. scientists who are or will be in the following jobs on a pediatric development project:
• Project Managers;
• Regulatory Specialists who prepare the regulatory documents;
• Scientists who develop the needed clinical studies, e.g. clinical scientists, pharmacokineticists, statisticians;
• Product Development Scientists and Managers who develop the pediatric formulations;
• Clinical Research Scientists and Associates who monitor the studies;
• Writers who develop manuscripts for publication;
• Physicians who provide medical expertise to the study; and
• Independent physicians who serve as investigators for the study.
• Review BPCA and PREA laws and changes under FDASIA
• Content of Pediatric Study Plans (PSP)
• FDA Review of PSP
• Compliance with PREA and BPCA
• Important links to relevant areas on FDA website
The area of pediatric development is relatively new and changing following the new laws. The use of adult data to support the pediatric initiative allows good adult information to support the children. This webinar will give you a good taste on what has happened recently.
WHO WILL BENEFIT
• Project Managers
• Regulatory Specialists
• Clinical Scientists
• Product Development Scientists
• Product Development Manages
• Clinical Research Scientists
• Clinical Research Associates
• Writers who develop manuscripts for publication
• Independent physicians who serve as investigators for the study
Robert L. Kunka, Ph. D. is an accomplished and respected scientist who contributed to the development of 28 approved pharmaceutical products in eight therapeutic areas. His expertise on international product development teams produced submissions with successful clinical strategies, sound matrix management of individual study teams, and effective interactions with regulatory agencies leading to successful IND, aNDA, and NDA approvals. Bob's experience in drug development stems from 24 years in the pharmaceutical industry at GlaxoSmithKline (GSK), Chugai-Upjohn, and GD Searle.
Prior to this, he was Assistant Professor at the University of Pittsburgh School of Pharmacy where he taught graduate and undergraduate courses in pharmacokinetics. Bob earned his Ph.D. in Pharmacokinetics at the University of North Carolina (UNC) at Chapel Hill and Bachelor of Science in pharmacy at the University of Illinois at the Medical Center in Chicago. While at UNC, he was honored to be named the American Foundation for Pharmaceutical Education Charles J Lynn and Syndor Barksdale Penick Memorial Fellow. Bob has been consulting (The Kunka Group, Inc.) since 2008.View all trainings by this speaker
Financial Statement Fraud and Identifying Red Flags
Speaker: Kenneth BardenPrice: $199
Moving from an Operational Manager to a Strategic Leader
Speaker: Chris DeVanyTime: 01:00 PM EDT | 10:00 AM PDT
Location: New York
Logistics Channel Incoterms Standards
Speaker: Dr. Rossano V. GeraldTime: 01:00 PM EDT | 10:00 AM PDT
Location: New York
Thank you for the spreadsheet webinar. The webinar was informative and helpful. Although many of the concepts are known and understood by Industrial and Process Engineers, it is always helpful to have a straightforward review. The spreadsheet will be beneficial in being able to help identify areas of risk and areas that may require some attention.
Benchmark Electronics , ******** Engineer
This was a very informative session, it did help my company by raising awareness in areas we lack policies. The only thing I would suggest get added to the session is direct information relating to Accounting, ex. Taxation rules for record retention as they are some records which a company is required to keep indefinitely.
First MCO, ***** Manager
Overall I found the video conference well organized and very informative. The presenter, Ronald Adler, was certainly extremely knowledgeable and presented the subject matter in a well organized, direct and succinct manner. Afford the attendee the ability to track and record paid attendance/activity without a lot of tracking and follow up in order to gather the necessary information required to record the CPEs earned and paid for.
Dynamic Marketing Systems, VP Finance & Human Resources
As this was our first experience, we did not know what to expect. I believe the webinar was informative and to the point, and explained to us the purpose of the I-9, and how the company can be affected by an audit. It really motivated us to review our files and bring them up to date.
Young Transportation, ****Coach****
I have participated in several webinars hosted by Compliance Global on various H&S topics. They are always precise, technologically-oriented, and easy to use and partake in to further my knowledge of current Health and Safety regulations and topics.